跳至主要内容
临床试验/JPRN-UMIN000008820
JPRN-UMIN000008820已完成1 期

Phase I study of peptide vaccination in patients with refractory gastrointestinal cancer - GI Peptide Vaccination

ational Cancer Center Hospital0 个研究点目标入组 18 人开始时间: 2012年9月3日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) active double cancer 2) active infection 3) pregnancy, the desire to preserve fecundity, or lactating woman 4) mental disorder 5) steroid treatment 6) uncontrolled diabetes mellitus 7) unstable angina or myocardial infarction within 6 months 8) other severe complications 9) active bleeding 10) massive ascites 11) massive pleural effusion 12) HBs antigen-positive

研究者

相似试验

已完成
1 期
Phase I study of peptide vaccination for patients with unresectable biliary tract cancerbiliary tract cancer
JPRN-UMIN000003229Tokyo Women's Medical University9
已完成
1 期
Phase I study of peptide vaccination for patients with biliary tract cancerbiliary tract cancer
JPRN-UMIN000003207Tokyo Women's Medical University9
已完成
1 期
Phase I study of peptide vaccination for patients with unresectable pancreatic cancerPancreatic cancer
JPRN-UMIN000004337Tokyo Women's Medical University9
进行中(未招募)
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6
进行中(未招募)
1 期
Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma
EUCTR2010-020435-40-BECentre du Cancer3
Phase I study of peptide vaccination in patients... | 临床试验